Tissue-type plasminogen activator: Variants and crystal/solution structures demarcate structural determinants of function

Current Opinion in Structural Biology

Volumn 7, Issue 6, 1997, Pages 865-872

  Bode, Wolfram ^a   Renatus, Martin ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME VARIANT; MUTANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; KRINGLE DOMAIN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031468345     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(97)80159-5     Document Type: Article

References (49)

1. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 301:1983;214-221.
2. Ny T, Eigh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc. Natl Acad Sci USA. 81:1984;5355-5359.
3. Horrevoets AJG, Smilde A, DeVries C, Pannekoek H. Mutants of tissue-type plasminogen activator during in vitro fibrinolysis. J Biol Chem. 269:1994;12639-12644.
4. Bakker AHF, Weening-Verhoeff EJD, Verheijen JH. The role of the lysyl binding site of tissue-type plasminogen activator in the interaction with a forming fibrin clot. J Biol Chem. 270:1995;12355-12360.
5. Gardell SJ, Duong LT, Diehel RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RA, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem. 264:1989;17947-17952.
6. Bringmann P, Gruber D, Liese A, Toschi L., Krätzschmar J, Schleuning W-D, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem. 270:1995;25596-25603.
7. Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant Escherichia coli-derived protease domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis. 10:1996;93-102.
8. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 78(suppl 12A):1996;2-7.
9. Davidson S. New clot busters threaten Genentech's PA. Nat Biotechnol. 15:1997;405-405.
10. Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller MJ. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem. 266:1991;5191-5201.
11. Madison EL. Probing structure/function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis. 8:1994;221-236.
12. Lijnen HR, Bachmann F, Collen D, Ellis V, Pannekoek H, Rijken DC, Thorsen S. Mechanisms of plasminogen activation. J Intern Med. 236:1994;415-424.
13. Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in mice. of outstanding interest Haemostasis. 26(suppl 4):1996;132-153 Presents a concise summary of gene-targeting studies in fibrinolysis and coagulation and discusses the derived role of the molecules involved.
14. 1H nuclear magnetic resonance. J Mol Biol. 225:1992;821-833.
15. De Vos AM, Ultsch MH, Kelley RF, Padmanabhan K, Tulinsky A, Westbrook ML, Kossiakoff AA. Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4 Å resolution. Biochemistry. 31:1992;270-279.
16. Byeon I-JL, Llinas M. Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic aicd and antifibrinolytic drug. J Mol Biol. 222:1991;1035-1051.
17. Smith BO, Downing AK, Driscoll PC, Dudgeon TJ, Campbell ID. The solution structure and backbone dynamics of the fibronectin type 1 and epidermal growth factor-like pair of modules of tissue-type plasminogen activator. Structure. 3:1995;823-833.
18. Lamba D, Bauer M, Huber R, Fischer S, Rudolph R, Kohnert U, Bode W. The 2.3 Å crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. of outstanding interest J Mol Biol. 258:1996;117-135 The exact structure of the proteolytic domain of human t-PA allows conclusions on specificity, plasminogen cleavage site geometry, ETI binding, single-chain stabilisation and kringle 2 domain attachment.
19. Renatus M, Bode W, Huber R, Stürzebecher J, Prasa D, Fischer S, Kohnert U, Stubbs MT. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. of outstanding interest J Biol Chem. 272:1997;21713-21719 The crystal structure of the 1-PA proteolytic domain in complex with a synthetic bis-benzamidine inhibitor is presented and shows that the S3/S4 groove of t-PA prefers arginine and phenylalanine sidechains, in agreement with t-PA's preference for D-Phe/Arg residues at P3.
20. Renatus M, Engh RA, Stubbs MT, Huber R, Fischer S, Kohnert U, Bode W. Lysine 156 promotes the anomalous proenzyme activity of t-PA: X-ray crystal structure of single-chain human t-PA. of outstanding interest EMBO J. 16:1997;4797-4805 Lys 156, in single-chain t-PA, is shown to form a buried salt bridge with Asp 194, whose "internal" placement is correlated with a functional binding site. A set of secondary interactions required for Lys 156 to fulfil its 'activating' role are indentified.
21. Renatus M, Stubbs MT, Huber R, Bringmann P, Donner P, Schleuning W-D, Bode W. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. of outstanding interest Biochemistry. 1997; In v-PA. Lys 156 shielded from bulk solvent by the noncleavable 'activation loop' is involved in salt-bridge formation with asp 194, whose 'internal' conformation is associated with a functional binding site. This 'activation' has the same molecular basis as the activity of the single-chain form of human t-PA.
22. Tachias K, Madison EL. Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin. J Biol Chem. 270:1995;18319-18322.
23. Tachias K, Madison EL. Converting tissue-type plasminogen activator into a zymogen. of outstanding interest J Biol Chem. 271:1996;28749-28752 This paper shows conclusively by mutating His144 to aspartate and glutamate that in the absence of fibrin His144 is of high importance for the catalytic activity of the single-chain form of t-PA.
24. Tachias K, Madison EL. Converting tissue-type plasminogen activator into a zymogen. of outstanding interest J Biol Chem. 272:1997;28-31 This paper shows by mutating Lys156 to tyrosine that Lys156 essentially contributes to the activity of single-chain t-PA and suggests mutations that might extend the therapeutic range.
25. Ahern TJ, Morris GE, Barone KM, Horgan PG, Timony GA, Angus LB, Henson KS, Stoudemire JB, Langer-Safer PR, Larsen GR. Site-directed mutagenesis in human tissue-type plasminogen activator. J Biol Chem. 265:1990;5540-5545.
26. Bassel-Duby R, Jiang NY, Bittick T, Madison E, McGookey D, Orth K, Shohet R, Sambrook J, Gething MJ. Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. J Biol Chem. 267:1992;9668-9677.
27. 1H-NMR. Biochemistry. 34:1995;2739-2750.
28. Hu C-K, Kohnert U, Stürzebecher J, Fischer S, Llinas M. Complexation of the tissue plasminogen activator protease with benzamidine-type inhibitors: interference by the kringle 2 module. Biochemistry. 35:1996;3270-3276.
29. Novokhatny VV, Ingham KC, Medved LV. Domain structure and domain - domain interactions of recombinant tissue plasminogen activator. J Biol Chem. 266:1991;12944-13002.
30. Margossian SS, Slayter HC, Kaczmarek E, McDonagh J. Physical characterization of recombinant tissue plasminogen activator. Biochim Biophys Acta. 1163:1993;250-256.
31. Ding L, Coombs GS, Strandberg L, Navre M, Corey DR, Madison EL. Origins of the specificity of tissue-type plasminogen activator. Proc Natl Acad Sci USA. 92:1995;7627-7631.
32. Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 339:1989;721-724.
33. Eastman D, Wurm FM, Van Reis R, Higgins DL. A region of tissue plasminogen activator that effects plasminogen activation differentially with various fibrin(ogen)-related stimulators. Biochemistry. 31:1992;419-422.
34. Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Bereleau LT, Badillo J, Pea LC, Brady K, Wurm FM, et al. A slow clearing. fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemostasis. 70:1993;307-312.
35. Stürzebecher J, Neumann U, Kohnert U, Kresse G-B, Fischer S. Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Protein Sci. 1:1992;1007-1013.
36. Spraggon G, Phillips C, Nowak UK, Ponting CP, Saunders D, Dobson CM, Stuart DI, Jones EY. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 3:1995;681-691.
37. Ke S-H, Coombs GS, Tachias K, Navre M, Corey DR, Madison EL. Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase. of outstanding interest J Biol Chem. 272:1997;16603-16609 This paper identifies, using a novel substrate subtraction, display library peptides (with arginine and serine-P3, respectively) that are particularly selective for either t-PA or u-PA and shows that corresponding substitutions in P3 and P4 render PAI-1 more t-PA specific.
38. Madison EL, Coombs GS, Corey DR. Substrate specificity of tissue type plasminogen activator. Characterization of the fibrin independent specificity of t-PA for plasminogen. J Biol Chem. 270:1995;7558-7562.
39. Coombs GS, Dang AT, Madison EL, Corey DR. Distinct mechanisms contribute to stingent substrate specificity of tissue-type plasminogen activator. J Biol Chem. 271:1996;4461-4467.
40. Ke S-H, Taschias K, Lamba D, Bode W, Madison EL. Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. of outstanding interest J Biol Chem. 272:1997;1811-1816 A hydrophobic edge located below the active-site cleft of t-PA makes an important secondary site for interaction with plasminogen.
41. Huber R, Bode W. Structural basis of the activation and action of trypsin. Acc Chem Res. 11:1978;114-122.
42. Bode W. The transition of bovine trypsinogen to a trypsinlike state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides of trypsinogen and to p-guanidinobenzoate-trypsinogen. J Mol Biol. 127:1979;357-374.
43. Nienaber VL, Young SL, Birkoft JJ, Higgins DL, Berliner LJ. Conformational similarities between one-chain and two-chain tissue plasminogen activator (t-PA): implications to the activation mechanism on one-chain t-PA. Biochemistry. 31:1992;3852-3861.
44. Madison El, Kobe A, Gething M-J, Sambrook JF, Goldsmith EJ. Converting tissue plasminogen activator to a zymogen: A regulatory triad of Asp-His-Ser. Science. 262:1993;419-421.
45. Grailhe P, Nieuwenhuizen W, Angles-Cano E. Study of tissue-type plasminogen activator binding sites of fibrin using distinct fragments of fibrinogen. Eur J Biochem. 219:1994;961-967.
46. Strandberg L, Madison EL. Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors. J Biol Chem. 270:1995;23444-23449.
47. Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr. 24:1991;946-950.
48. Turk D: Weiterentwicklung eines Programmes für Molekülgrafik und Elektronendichte-Manipulation und seine Anwendung auf verschiedene Protein-Strukturaufklärungen [PhD Thesis]. Müchen: Technische Universität München; 1992. [Title translation: Further development of a program for molecular graphics and electron-density manipulation and it use in determining different protein structures.].
49. Krätzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, Donner P, Schleuning W-D. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene. 105:1991;229-237.